cholecalciferol and Phosphorus-Metabolism-Disorders

Valvular calcification in chronic haemodialysis patients has already been reported in the literature, particularly the abnormally high incidence of aortic stenosis. In this study, 112 haemodialysis patients were followed up by Doppler echocardiography for a period of 36 months. Sixteen patients developed aortic valvular calcification with aortic stenosis over an 18.7 +/- 7.5 months period. The indexed aortic valve surface area decreased from 1.24 +/- 0.9 cm2/m2 to 0.66 +/- 0.21 cm2/m2 with abnormally rapid progression. Eight patients with aortic stenosis died during the 3 year study period. These results reflect the abnormal extra-skeletal calcification of chronic haemodialysis patients. Several predisposing factors were demonstrated: age (68.5 +/- 11.1 years versus 57.1 +/- 16.3 years in patients without calcifications), male gender, a longer period of dialysis than the patients without aortic stenosis (8.1 +/- 5.3 versus 5.9 +/- 5.7 years), abnormalities of calcium and phosphate metabolism, increased of the phosphocalcic product by hyperphosphoraemia and not by hypercalcaemia, hypoparathyroidism in 62% and hyperparathyroidism in 38% an increase in vitamin D 3 (19.7 +/- 14 ng/ml versus 9.6 +/- 6.3 ng/ml) biological signs of adynamic osteodystrophy. Calcific aortic stenosis is a commonly observed valvular lesion in haemodialysis patients: its progression may be very rapid, associated with a poor prognosis. Old age, male gender, duration of haemodialysis, hyperphosphataemia associated with hypoparathyroidism and raised Vitamin D3 are predisposing factors.

Topics: Aged; Aged, 80 and over; Aortic Valve Stenosis; Calcinosis; Calcium Metabolism Disorders; Cholecalciferol; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Male; Middle Aged; Phosphorus Metabolism Disorders; Prognosis; Renal Dialysis; Risk Factors; Ultrasonography

Male Wistar rats that were experimentally hypokinetic were fed 24,25(OH)2D3 or 1,25(OH)2D3 separately or in combination to determine the effect on bone growth and on bone formation and resorption. It was shown that these parameters of bone metabolism are influenced by these metabolites of vitamin D3 by their effect on bone sensitivity to their activity and perhaps in the regulation of bone histogenesis.

Topics: 24,25-Dihydroxyvitamin D 3; Animals; Bone Development; Calcitriol; Calcium Metabolism Disorders; Cholecalciferol; Dihydroxycholecalciferols; Epiphyses; Femur; Growth Plate; Immobilization; Male; Movement; Phosphorus Metabolism Disorders; Rats; Rats, Inbred Strains

Topics: Calcium Metabolism Disorders; Cholecalciferol; Chronic Kidney Disease-Mineral and Bone Disorder; Ergocalciferols; Humans; Hypoparathyroidism; Osteomalacia; Osteoporosis; Phosphorus Metabolism Disorders; Renal Dialysis; Vitamin D

Topics: Animals; Cholecalciferol; Chromatography, Gel; Chromatography, Paper; Phosphorus; Phosphorus Metabolism Disorders; Plant Extracts; Plant Poisoning; Plants; Rabbits; Solvents

Topics: Animals; Calcium; Cholecalciferol; Phosphorus; Phosphorus Metabolism Disorders; Sheep; Sheep Diseases; Trichostrongyloidiasis

Topics: Adolescent; Body Height; Bone Diseases; Calcium; Child; Cholecalciferol; Diagnosis, Differential; Female; Humans; Hyperparathyroidism; Hypocalcemia; Hypoparathyroidism; Phosphorus Metabolism Disorders; Tetany